LUNG CANCER

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for Medical Oncology Congress 2024, shedding light on potential strategies for managing EGFR-mutated and MET-amplified non–small cell lung cancer.

An expert addressed the emerging role of immune checkpoint inhibitors in the perioperative space based on findings from the CheckMate 816, IMpower010, PEARLS, and ADAURA trials.

Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor vs placebo plus chemotherapy in patients with early-stage non–small cell lung cancer.

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer, according to data from an interim analysis of the phase 3 POLESTAR trial.

Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced non-small cell lung cancer.

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung cancer setting in the second article of a 2-part series.

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in patients with metastatic non–small cell lung cancer.

Nicolas Girard, MD, PhD, discusses patient-reported outcomes from the LUMINOSITY trial of telisotuzumab vedotin in NSCLC.

Nicolas Girard, MD, PhD, discusses the rationale of targeting PD-L1 and LAG-3 in NSCLC in the RELATIVITY-104 study.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell lung cancer, based on data from the phase 3 CheckMate 77T trial.

Hatim Husain, MD, discusses how acquired resistance to kinase inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) poses a significant challenge in long-term treatment efficacy, necessitating ongoing research into novel therapeutic strategies and combination approaches to overcome resistance mechanisms.

Percy Lee, MD, discussed findings from a trial evaluating a hypofractionated approach to concurrent chemoradiation, incorporating an adaptive stereotactic ablative radiotherapy boost in non–small cell lung cancer.

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.

Xiuning Le, MD, PhD, delved into the background, findings, and next steps of the SOHO-01 study.

The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.

The GigaPath AI model was highlighted for its advanced capabilities in predicting cancer mutations and tumor mutation burden, including those in lung cancer and other malignancies.

Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on overall survival outcomes in patients with lung cancer, with a particular focus on survival rates across different histological subtypes.

Panelists discuss how the HARMONi-02 trial presented at World Conference on Lung Cancer 2024 revealed key lung cancer insights, focusing on progression-free survival and immune-related response criteria end points, while emphasizing the trial’s significance for specific patient subgroups.

Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.

Panelists discuss how the latest outcomes from CheckMate-77T demonstrate improved efficacy of neoadjuvant immunotherapy in early-stage non–small cell lung cancer compared with CheckMate-816, potentially revolutionizing treatment strategies and enhancing long-term survival rates for patients with lung cancer.

The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.

In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.

Adagrasib demonstrated superior outcomes to docetaxel in patients with previously treated KRAS G12C-mutated non-small cell lung cancer, even among those with baseline brain metastases.